EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Maike H M Wientjes, Sadaf Atiqi, Gerrit J Wolbink, Michael T Nurmohamed, Maarten Boers, Femke Hooijberg, Theo Rispens, Annick de Vries, Ronald F van Vollenhoven, Sofia Ramiro, Noortje van Herwaarden, Bart J F van den Bemt und 1 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.03.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Maike H M Wientjes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands. Electronic address: m.wientjes@maartenskliniek.nl. Hauptthemen laut MEDLINE: Adalimumab, Arthritis, Rheumatoid, Antirheumatic Agents, Drug Substitution. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Netherlands Organisation for Health Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: A substantial proportion of patients with rheumatoid arthritis (RA) discontinue adalimumab due to ineffectiveness. The next treatment step can be another tumour necrosis factor inhibitor (TNFi) or a biological/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD). Therapeutic drug monitoring (TDM) of serum drug levels may help guide this choice. This study evaluated whether switching treatments based on adalimumab trough levels is more effective than random switching. METHODS: In this 24-week, multicentre, triple-blinded, randomised controlled trial, patients with RA who stopped adalimumab due to inefficacy (disease activity score based on 28 joint count and C-reactive protein [DAS28-CRP] >2.9) were enrolled. Participants were randomly assigned (1:1) to a TDM-based or random switching (control) strategy. The primary outcome was the difference in mean time-weighted DAS28-CRP between groups at 24 weeks. RESULTS: From July 2020 to November 2023, 83 consecutive patients with RA were included, with 78 initiating a new b/tsDMARD (TDM-based group: n = 38; control: n = 40). The mean time-weighted DAS28-CRP was 3.15 in both groups (TDM: SD, 0.99; control: SD, 1.01; 95% CI of difference: -0.46 to 0.47). There were no significant differences between the groups in flare rates, escape medication use, disease activity, or adverse events. Receiver operating characteristic analyses in the control group found no predictive value of adalimumab levels for response to TNFi or non-TNFi. CONCLUSIONS: Switching treatments based on adalimumab trough levels was not more effective than random switching in patients with RA who failed adalimumab treatment. Therefore, serum drug level measurements to guide therapy choices in this context is not recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabArthritis, RheumatoidAntirheumatic AgentsDrug SubstitutionHumansFemaleMaleMiddle AgedDrug MonitoringAdultAgedTreatment OutcomeC-Reactive Protein

Substanzen

AdalimumabAntirheumatic AgentsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands. Electronic address: m.wientjes@maartenskliniek.nl.
  • Department of Rheumatology, Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, the Netherlands.
  • Department of Rheumatology, Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, the Netherlands; Sanquin Research, Sanquin, Amsterdam, the Netherlands.
  • Department of Rheumatology, Amsterdam Rheumatology and Immunology Centre, Reade, Amsterdam, the Netherlands; Antibodies and Immunogenicity, R&D, Sanquin Diagnostic Services, Amsterdam, the Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, the Netherlands.
  • Sanquin Research, Sanquin, Amsterdam, the Netherlands; Antibodies and Immunogenicity, R&D, Sanquin Diagnostic Services, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherla…

Förderung

  • Netherlands Organisation for Health Research and Development

Zitieren

APA

Wientjes, M. H. M., Atiqi, S., Wolbink, G. J., Nurmohamed, M. T., Boers, M., Hooijberg, F., Rispens, T., de Vries, A., van Vollenhoven, R. F., Ramiro, S., van Herwaarden, N., van den Bemt, B. J. F., & den Broeder, A. A. (2025). Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.03.015

Vancouver

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, et al. Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.03.015

BibTeX
@article{Wientjes2025,
  author = {Wientjes, Maike H M and Atiqi, Sadaf and Wolbink, Gerrit J and Nurmohamed, Michael T and Boers, Maarten and Hooijberg, Femke and Rispens, Theo and de Vries, Annick and van Vollenhoven, Ronald F and Ramiro, Sofia and van Herwaarden, Noortje and van den Bemt, Bart J F and den Broeder, Alfons A},
  title = {Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.03.015}
}
Kostenlos starten →